Photo: iStock
A new study presented at the World Cancer Conference in San Antonio in the United States (SABCS) found that women with advanced and metastatic breast cancer treated with the drug “Anharto” were able to survive more than 20 months from receiving treatment.
News 12 reported that the US Food and Drug Administration (FDA) approved the treatment in a flash procedure in light of the drug’s high efficacy and may even be included in the health basket in Israel this year.
According to the interim results, 74% of the patients who took “Anharto” survived more than 18 months from the time of receiving the treatment and it is estimated that the patients’ life span will be significantly longer in the last stage of the study.
“The results of the study show us that there is still a good treatment option for patients with metastatic breast cancer,” said Dr. Shano Moody, a breast cancer oncologist at Memorial Sloan Kettering Hospital in New York and the lead researcher. This is important, because there are almost no treatments for cancer that have succeeded in prolonging the lives of patients at this stage of the disease. “
Over a thousand women in Israel die each year from the disease and only 27% of women with metastatic breast cancer survive more than five years.